Chitosan Oligosaccharide Nanoparticles

ROS-Responsive Dual-Drug

A boronic acid and thioketal crosslinked nanocarrier that rapidly releases two drugs under high ROS and accumulates in renal tubules, enabling precise combination therapy for diabetic nephropathy.

Weibin, Shao · Yiming, Zhang · Changyu, Yao · Jiaqi, Kan · Chi, Zhang · Tang, Rupei

Carbohydrate Polymers 2026

Specifications

Particle size

{'zh': '110', 'en': '110'} nm

EGCG loading efficiency

{'zh': '16.6', 'en': '16.6'} %

CAN loading efficiency

{'zh': '10.1', 'en': '10.1'} %

Cumulative drug release

{'zh': '70', 'en': '70'} %

Advantages

Size matched to renal tubules

The ~110 nm size promotes accumulation in the kidneys and uptake by renal tubular epithelial cells, delivering drugs to the site of injury.

On-demand dual-drug release

The thioketal crosslinks cleave under high ROS, triggering rapid co-release of EGCG and CAN for synergistic therapy.

Intracellular antioxidant protection

After uptake by HK-2 cells, the nanoparticles significantly reduce intracellular ROS and suppress oxidative stress-induced apoptosis.

Applications

• Diabetic nephropathy therapy：Achieves precise treatment by responding to oxidative stress while alleviating renal pathological damage.
• Combination drug delivery：Co-delivers EGCG and CAN for synergistic antioxidant and hypoglycemic effects.
• ROS-responsive delivery：Thioketal crosslinks cleave under high ROS, enabling release triggered by the pathological microenvironment.
• Renal-targeted nanoparticles：The 110 nm size promotes renal accumulation and tubular uptake, enhancing local drug concentration.